TSX runs higher on rate cut expectations
Director Erck Stanley C. of MAXCYTE, INC. (NASDAQ:MXCT) purchased 100,000 shares of common stock on August 13, 2025, in a transaction valued at $137,220. The timing is notable as InvestingPro data shows the stock has declined over 66% in the past six months, with current analysis indicating the shares are undervalued.
The shares were bought in multiple transactions at prices ranging from $1.29 to $1.44. Following the transaction, Erck Stanley C. directly owns 398,328 shares of Maxcyte stock. The company, currently valued at $147 million, maintains strong liquidity with a current ratio of 12.39 and more cash than debt on its balance sheet. InvestingPro analysis reveals 11 additional key insights about MXCT’s financial health and market position, available in the comprehensive Pro Research Report.
In other recent news, MaxCyte Inc. reported its second-quarter earnings for 2025, revealing a revenue shortfall. The company posted revenue of $8.5 million, which missed the forecasted $9.63 million by 11.73%. Earnings per share were reported at -$0.12, slightly below the expected -$0.10. MaxCyte also reduced its 2025 revenue guidance by $5 million, indicating a 14% reduction in its business outlook. Analysts have responded to these developments with downgrades. BTIG downgraded MaxCyte from Buy to Neutral, citing ongoing funding challenges for the company’s clients. Similarly, William Blair downgraded the stock from Outperform to Market Perform due to weak guidance and disappointing performance. The revised guidance suggests a decline in core organic revenue by 6%-16% for the year, including a 20% drop in the second half.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.